We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.44%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$952M
AUM Growth
+$53.7M
Cap. Flow
-$41M
Cap. Flow %
-4.31%
Top 10 Hldgs %
58.55%
Holding
72
New
9
Increased
10
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$17.9M
2
PCYC
PHARMACYCLICS INC
PCYC
+$11.9M
3
IBB icon
iShares Biotechnology ETF
IBB
+$11.1M
4
INCY icon
Incyte
INCY
+$7.27M
5
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$6.88M

Top Sells

Rank Stock Value
1
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$16.3M
2
PBYI icon
Puma Biotechnology
PBYI
+$16M
3
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$15.5M
4
MRK icon
Merck
MRK
+$14.1M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$9.41M

Sector Composition

Rank Sector Weight
1 Healthcare 89.95%
2 Miscellaneous 8.27%
3 Financials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVNR
51
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.36M 0.14%
406,000
-554,000
-58% -$2.29M
TMO icon
52
Thermo Fisher Scientific
TMO
$237B
$1.11M 0.12%
+9,980
New +$992K
RVTY icon
53
Revvity
RVTY
$15.6B
$1.08M 0.11%
+26,300
New +$1.01M
SUPN icon
54
Supernus Pharmaceuticals
SUPN
$2.4B
$1.06M 0.11%
140,800
– –
WAT icon
55
Waters Corp
WAT
$41B
$970K 0.1%
+9,700
New +$978K
ACHV icon
56
Achieve Life Sciences
ACHV
$753M
$943K 0.1%
51
– –
MGNX icon
57
MacroGenics
MGNX
$257M
$786K 0.08%
+31,857
New +$833K
AMRN
58
Amarin Corp
AMRN
$294M
– –
-69,586
Closed -$8.8M
BAX icon
59
Baxter International
BAX
$12.3B
– –
-143,000
Closed -$5.1M
ICAD
60
DELISTED
iCAD Inc
ICAD
– –
-88,527
Closed -$467K
MDGL icon
61
Madrigal Pharmaceuticals
MDGL
$12.1B
– –
-13,993
Closed -$3.09M
MRK icon
62
Merck
MRK
$355B
– –
-310,858
Closed -$14.1M
ARIA
63
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-412,965
Closed -$7.6M
AEGR
64
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-11,880
Closed -$1.02M
QCOR
65
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-162,328
Closed -$9.41M
GENT
66
DELISTED
GENTIUM SPA ADS
GENT
– –
-64,543
Closed -$1.75M
ELN
67
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
– –
-242,500
Closed -$3.78M
ONXX
68
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-124,238
Closed -$15.5M
WCRX
69
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
– –
-713,797
Closed -$16.3M
RPTP
70
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-110,000
Closed -$1.64M
MDVN
71
DELISTED
MEDIVATION, INC.
MDVN
– –
-184,400
Closed -$5.53M
CERE
72
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
– –
-35,748
Closed -$426K
1 2
3

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Tekla Capital Management held 72 positions worth $952M, up 6% from $899M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Tekla Capital Management withdrew a net $41M in Q4 2013, closing 15 positions and reducing 8 holdings. Its most notable exit was WARNER CHILCOTT PLC ORD SHS CL A (IRL), an estimated $16.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Tekla Capital Management opened a new position in PHARMACYCLICS INC worth $10.4M.

  • Tekla Capital Management's largest Q4 2013 buy was PHARMACYCLICS INC: 98,000 shares worth $10.4M.
  • Tekla Capital Management added most to Allergan plc in Q4 2013, an estimated $17.9M increase.
  • Tekla Capital Management's biggest Q4 2013 reduction was Puma Biotechnology, cutting an estimated $16M.
  • Tekla Capital Management fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $16.3M.
  • Tekla Capital Management's ten largest holdings make up 59% of its $952M portfolio in Q4 2013.
  • Tekla Capital Management opened 9 new positions and closed 15 in Q4 2013.
  • Tekla Capital Management's portfolio value rose 6% quarter-over-quarter to $952M.

Based on Tekla Capital Management's 13F filing for Q4 2013, filed 28 Jan 2014.